儿童生长贴联合重组人生长激素治疗特发性矮小症的疗效

中国现代医生2019年4月第57卷第10期·妇幼医学·

特发性矮小症(idiopathic short stature,ISS)是指个体身高低于同年龄、同性别、同种族儿童身高的平均值2SD以上或低于第3百分位,无全身性、内分泌、营养性疾病或染色体异常的状况,且生长激素(GH)水平正常[1]。越来越多的证据[2-3]表明,促生长激素释放激素-生长激素-胰岛素样生长因子1(GHRH-GH-IGF1)内分泌轴的功能异常可能与ISS的发生发展密切相关。目前治疗ISS的药物主要为人重组生长激素,且取得了显著疗效[4]。近年来,儿童生长贴在临床上得到广泛应用,但临床效果如何,目前文献报道尚少。本研

儿童生长贴联合重组人生长激素治疗特发性

矮小症的疗效

朱灵芝1茹锦岩1俞慧君2叶建敏2陈秀芳1冯海英2▲

1.台州恩泽医疗中心(集团)路桥医院儿童生长发育科,浙江台州318050;

2.台州恩泽医疗中心(集团)恩泽医院儿童生长

发育科,浙江台州318050

[摘要]目的探讨儿童生长贴联合重组人生长激素对特发性矮小症的治疗效果。方法回顾性分析2016年2月~ 2017年2月我科因特发性矮小症就诊的患儿45例;按治疗方法分为对照组、观察组1、观察组2各15例,对照组为拒绝一切药物治疗者,观察组1为采用儿童生长贴治疗的患儿;观察组2为采用生长贴联合重组人生长激素治疗的患儿,疗程均为12个月。比较身高增长值、遗传身高、预测成年身高。结果对照组、观察组1和观察组

2比较,身高增长值分别为(3.87±1.25)cm、(7.93±1.53)cm、(10.20±1.97)cm,差异有显著性(F=59.48,P<0.01);遗传身高分别为(156.80±4.94)cm、(156.07±3.97)cm、(156.13±4.58)cm,差异无显著性(F=0.12,P>0.05);成年预测身高分别为(155.73±3.31)cm、(164.80±5.24)cm、(167.87±5.68)cm,差异有显著性(F=25.35,P<0.01)。结论儿童生长贴联合重组人生长激素治疗特发性矮小症可显著增加患儿身高增长值,提高其成年身高预测值。

[关键词]儿童生长贴;重组人生长激素;特发性矮小症;身高增长值

[中图分类号]R725.8[文献标识码]B[文章编号]1673-9701(2019)10-0059-03 Therapeutic effect of children's growth patch combined with recombinant human growth hormone in treatment of idiopathic short stature

ZHU Lingzhi1RU Jinyan1YU Huijun2YE Jianmin2CHEN Xiufang1FENG Haiying2

1.Department of Children's Growth and Development,Taizhou Enze Medical Center(Group)Luqiao Hospital,Taizhou 318050,China;

2.Department of Children's Growth and Development,Taizhou Enze Medical Center(Group)Enze Hos⁃pital,Taizhou318050,China

[Abstract]Objective To investigate the therapeutic effect of children's growth patch combined with recombinant hu⁃man growth hormone on idiopathic short stature.Methods A retrospective analysis of45children patients with idio⁃pathic short stature from February2016to February2017was carried out,according to the treatment method,they were divided into the control group,the observation group1and the observation group2,with15cases in each group.The control group was those who rejected all medications.The observation group1was those who were given children's growth patch;the observation group2was those who were given growth patch combined with recombinant human growth hormone therapy.The treatment lasted for12months.The height growth,genetic height,and predicted adult height were compared.Results The control group,the observation group1and the observation group2were compared, and the height growth values were(3.87±1.25)cm,(7.93±1.53)cm,and(10.20±1.97)cm,respectively,and the difference was significant(F=59.48,P<0.01);the genetic heights were(156.80±4.94)cm,(156.07±3.97)cm,(156.13±4.58)cm,re⁃spectively,and the difference was not significant(F=0.12,P>0.05);the predicted adult heights were(155.73±3.31)cm, (164.80±5.24)cm,and(167.87±5.68)cm,respectively,and the difference was significant(F=25.35,P<0.01).Conclusion Children's growth patch combined with recombinant human growth hormone in the treatment of idiopathic short stature can significantly increase the height growth value and increase the predicted value of adult height.

[Key words]Children's growth patch;Recombinant human growth hormone;Idiopathic short stature;Height growth

[基金项目]浙江省中医药科学研究基金项目(2018ZA131)

▲通讯作者